...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials
【24h】

Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials

机译：大麻肽在成人中的剂量，疗效和安全性：对人类试验的系统审查

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Considering data from in vitro and in vivo studies, cannabidiol (CBD) seems to be a promising candidate for the treatment of both somatic and psychiatric disorders. The aim of this review was to collect dose(s), dosage schemes, efficacy and safety reports of CBD use in adults from clinical studies. A systematic search was performed in PubMed, Embase and Cochrane library for articles published in English between January 1, 2000 and October 25, 2019. The search terms used were related to cannabis and CBD in adults. We identified 25 studies (927 patients; 538 men and 389 women), of which 22 studies were controlled clinical trials (833 patients) and three were observational designs (94 patients) from five countries. Formulations, dose and dosage schemes varied significantly between studies. Varying effects were identified from the randomized controlled trials (RCTs), more apparent effects from non-RCTs and minor safety issues in general. From the controlled trials, we identified anxiolytic effects with acute CBD administration, and therapeutic effects for social anxiety disorder, psychotic disorder and substance use disorders. In general, studies were heterogeneous and showed substantial risks of bias. Although promising results have been identified, considerable variation in dosage schemes and route of administration were employed across studies. There was evidence to support single dose positive effect on social anxiety disorder, short medium-term effects on symptomatic improvement in schizophrenia and lack of effect in the short medium-term on cognitive functioning in psychotic disorders. Overall, the administration was well tolerated with mild side effects.Copyright 2020, Larsen et al.
机译：考虑来自体外和体内研究的数据，大麻（CBD）似乎是治疗体细胞和精神病疾病的有希望的候选者。本综述的目的是收集来自临床研究的成人中CBD使用的剂量，剂量方案，疗效和安全报告。在2019年1月1日至10月25日之间以英语发表的文章进行了系统搜索。使用的搜索条件与大麻和成年人的CBD相关。我们鉴定了25项研究（927名患者; 538名男性和389名女性），其中22项研究受到控制临床试验（833名患者），三个是来自五个国家的观察设计（94名患者）。在研究之间的配方，剂量和剂量方案变化显着变化。从随机对照试验（RCT）鉴定出不同效果，从非RCT和次要安全问题中的更明显的影响。从受控试验中，我们鉴定了急性CBD给药的抗焦虑作用，以及社会焦虑症，精神障碍和物质使用障碍的治疗效果。一般来说，研究是异质的并且显示出偏差的大量风险。虽然已经确定了有希望的结果，但在研究中使用了相当大的剂量方案和给药途径。有证据表明对社会焦虑症的单剂量积极作用，短期影响对精神分裂症的症状性改善以及在精神病疾病中的认知功能中的短期中期缺乏效果。总体而言，施用良好的副作用良好。柔毛2020，Larsen等。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号